Use of an anti‐D‐alloimmunization kinetics model to correct the interval censored D‐alloimmunization rate following red blood cell transfusions
Transfusion · 2025
DOI: 10.1111/trf.18138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Emil Ainsworth Jochumsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Isoantibodies, Rh-Hr Blood-Group System, Rho(D) Immune Globulin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The rate of D‐alloimmunization amongst RhD‐negative recipients of RhD‐positive red blood cell (RBC) transfusions is not certain. Recipients with a short duration between the index RhD‐positive transfusion and the last antibody detection test that did not show anti‐D might become D‐alloimmunized in the future. A regression model was developed to predict how often such patients might develop D‐alloimmunization in the future to help account for the immunohematological uncertainty that accompanies having short serological follow up periods.
Methods
Using the published literature on recipients who were intentionally transfused with RhD‐positive RBCs and serially followed with antibody screens, as well as unpublished datasets, a regression model was constructed to demonstrate the timing of D‐alloimmunization for recipients who became D‐alloimmunized within 6 months following the index transfusion. The model was then applied to a series of RhD‐negative hospitalized recipients of at least one unit of RhD‐positive RBCs who did not become D‐alloimmunized but who had fewer than 6 months of serological follow up to weight their contribution to the D‐alloimmunization rate.
Results
Overall, the rate of D‐alloimmunization was 21/105 (20.0%). There were 39 patients whose last documented antibody screen was performed between 14 days and 6 months after the index RhD‐positive transfusion, and these patients were entered into the weighted model. After applying the model, the D‐alloimmunization rate rose to 26.3%.
Conclusion
Using a weighted model can help reduce the immunohematological uncertainty that accompanies the inclusion of patients with relatively short serological follow up in studies of RBC alloimmunization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
- Institute of Transfusion Medicine, University Hospital Greifswald, Greifswald, Germany.
- Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
- Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.
- Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
- Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Emil Ainsworth Jochumsen, Carolina Bonet Bub, Ulrik Sprogøe, Mark H Yazer
Zitieren
APA
Jochumsen, E. A., Selleng, K., Raval, J. S., Bub, C. B., Kutner, J. M., Sprogøe, U., & Yazer, M. H. (2025). Use of an anti‐D‐alloimmunization kinetics model to correct the interval censored D‐alloimmunization rate following red blood cell transfusions. Transfusion. https://doi.org/10.1111/trf.18138
Vancouver
Jochumsen EA, Selleng K, Raval JS, Bub CB, Kutner JM, Sprogøe U, et al. Use of an anti‐D‐alloimmunization kinetics model to correct the interval censored D‐alloimmunization rate following red blood cell transfusions. Transfusion. 2025. doi:10.1111/trf.18138
BibTeX
@article{Jochumsen2025,
author = {Jochumsen, Emil Ainsworth and Selleng, Kathleen and Raval, Jay S and Bub, Carolina Bonet and Kutner, Jose M and Sprogøe, Ulrik and Yazer, Mark H},
title = {Use of an anti‐D‐alloimmunization kinetics model to correct the interval censored D‐alloimmunization rate following red blood cell transfusions},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18138}
}
EUVIMED